6th Annual Gulf-Atlantic Veterinary Conference
Appetite is often a key determinant in a pet owners’ perceived quality-of-life evaluation for their dog or cat with cancer or other chronic diseases. Lack of appetite is often the first recognizable sign by pet owners that their dog or cat is not feeling well and often triggers inquiry to their veterinarian’s office. Inappetence in pets with chronic disease is often multifactorial with potential underlying causes including: cancer, chronic kidney disease, congestive heart failure, inflammatory bowel disease, or secondary to other mediations/treatments, including chemotherapy. Recent availability of capromorelin (ghrelin agonist), an appetite stimulant approved by the FDA for use in dogs, provides a new tool to help manage this important clinical sign. Reviewing the mechanism of action and dosing, practical integration of capromorelin (ENTYCE) for appetite stimulation, quality-of-life improvement and potential cachexia management in both dogs and cats will be outlined with case examples.